FDA 483 OBSERVATION · #181 OF 1,945 MOST-CITED

Reports of Analysis (Components)

FDA cited this observation 172 times across 152 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Drugs172
BY FISCAL YEAR
FY20263
FY202524
FY202428
FY202317
FY202212
FY20219
FY20208
FY201921
FY201814
FY201719
FY201617

What this observation is associated with

Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 6.3× the rate of the average FDA-cited firm (49.3% vs 7.8%), across 152 FEI-matched firms.

This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.

CHECKING ACCESS

Checking your access…

How FDA worded it — real examples

Reports of analysis from component suppliers are accepted in lieu of testing each component for conformity with all appropriate written specifications, without performing at least one specific identity test on each component and establishing the reliability of the supplier's analyses through appropriate validation of the supplier's test results at appropriate intervals.

Cosmoceutical Research Center, Inc. · Panorama City, California · Drugs · 2026-05-29

Reports of analysis from component suppliers are accepted in lieu of testing each component for conformity with all appropriate written specifications, without performing at least one specific identity test on each component and establishing the reliability of the supplier's analyses through appropriate validation of the supplier's test results at appropriate intervals.

Chartwell Pharmaceuticals Congers, LLC · Congers, New York · Drugs · 2025-11-18

Reports of analysis from component suppliers are accepted in lieu of testing each component for conformity with all appropriate written specifications, without performing at least one specific identity test on each component and establishing the reliability of the supplier's analyses through appropriate validation of the supplier's test results at appropriate intervals.

Embecta Medical 1, LLC. · Holdrege, Nebraska · Drugs · 2025-10-17

Reports of analysis from component suppliers are accepted in lieu of testing each component for conformity with all appropriate written specifications, without performing at least one specific identity test on each component and establishing the reliability of the supplier's analyses through appropriate validation of the supplier's test results at appropriate intervals.

Central Admixture Pharmacy Services, Inc. · Allentown, Pennsylvania · Drugs · 2025-09-05

Reports of analysis from component suppliers are accepted in lieu of testing each component for conformity with all appropriate written specifications, without performing at least one specific identity test on each component and establishing the reliability of the supplier's analyses through appropriate validation of the supplier's test results at appropriate intervals.

RC Outsourcing, LLC · Lowellville, Ohio · Drugs · 2025-08-28

Reports of analysis from component suppliers are accepted in lieu of testing each component for conformity with all appropriate written specifications, without performing at least one specific identity test on each component and establishing the reliability of the supplier's analyses through appropriate validation of the supplier's test results at appropriate intervals.

Chemco Corporation · Miami Lakes, Florida · Drugs · 2025-08-22

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Pharma industry →

Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →